



**Announcement of Interest to Receive Independent Medical Education (IME) Grant Applications**

**Release Date: April 2026 --- Due Date: May 2026**

Boehringer Ingelheim Pharmaceuticals, Inc. is committed to supporting innovative, high quality, independent medical education (IME) for healthcare professionals that helps address unmet medical needs, maintains clinical excellence, and aims to improve patient health outcomes in BIPI's therapeutic areas of interest.

**The intent of this Request for Proposals (RFP) announcement is to notify experienced and eligible medical education providers that Boehringer is interested in receiving applications for IME activities pertinent to Interstitial Lung Disease and aligned to the specifications outlined below.**

Such IME must be based on identified educational needs of healthcare provider-learners, be evidence-based in the aim to improve the care of patients and may or may not offer continuing education (CE) credit. Importantly, Boehringer supported IME must adhere to relevant regulatory guidance and industry standards.

Grant applications must be submitted through the BIPI funding portal at [www.bipigrants.com](http://www.bipigrants.com) Once received, Boehringer will carefully consider each request with a goal to provide a decision no more than 60 days from receipt. This is a competitive award, and as such, the outcome of each review may result in full support, partial funding, or in a denial decision.

Unless otherwise noted on [www.bipigrants.com](http://www.bipigrants.com), during the period of this RFP and throughout the year, Boehringer will also accept requests from eligible organizations that are not in response to an RFP. Should those grant applications be received during the time of this RFP and align with the parameters outlined in this announcement, Boehringer will review those applications and evaluate them according to the same quality and eligibility standards.

If you have questions about the RFP application process, please send an email to the Boehringer Ingelheim Pharmaceuticals Funding Mailbox at [medfunding.us@boehringer-ingelheim.com](mailto:medfunding.us@boehringer-ingelheim.com)

**Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)**

RFP (Request for Proposals) Posting Date	April 2026
RFP Submission Deadline	Accepted on an <b>ongoing</b> basis until <b>May 11, 2026</b> . Review is prioritized based on date of receipt, program requirements and available budget.
Therapeutic Area	Pulmonology/Rheumatology
Disease State	Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Systemic Autoimmune Rheumatic Disease Associated ILD (SARD-ILD)
Educational Focus  <i>(Educational activities should address one or more of the following educational gaps):</i>	<p><b>1. Pathophysiology, Prevalence, Burden of Disease</b></p> <ul style="list-style-type: none"> <li>• Increase clinician knowledge of the pathophysiology, prevalence, morbidity, mortality, and signs and symptoms of fibrosing ILDs (e.g. IPF, PPF, SARD-ILD).</li> </ul> <p><b>2. Diagnosis</b></p> <ul style="list-style-type: none"> <li>• Increase clinician knowledge of updated screening and diagnostic guidelines and competence in delivering standardized diagnostic approaches and testing methods (e.g. high-resolution computed tomography).</li> <li>• Increase clinician competence and confidence in interpreting diagnostic tests to enable earlier ILD identification and differentiate between subtypes.</li> </ul> <p><b>3. Clinical Management</b></p> <ul style="list-style-type: none"> <li>• Increase clinician knowledge and confidence in the evidence supporting the current therapeutic landscape for fibrosing ILDs, including screening, diagnosis, follow-up, management, and the appropriate use of supplemental oxygen therapy.</li> <li>• Increase competence and confidence in delivering routine follow-up assessments in patients with fibrosing ILDs to promptly identify acute exacerbations and disease progression.</li> <li>• Increase clinician competence and confidence in effective communication and education of fibrosing ILD patients and their caregivers about their disease.</li> <li>• Increase clinician competence and performance of multidisciplinary care through coordinated treatment planning, community building, and collaborative learning environments among rheumatologists, pulmonologists, and other interdisciplinary teams.</li> </ul>

**Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)**

	<p><b>References</b></p> <p>1. Cottin V, Martinez FJ, Smith V, Walsh SLF. Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives. Eur Respir Rev. 2022 Sep 7;31(165):220003. doi: 10.1183/16000617.0003-2022. PMID: 38743511.</p> <p>2. De Lorenzis E, Bosello SL, Varone F, et al. Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement. Diagnostics (Basel). 2020 Sep 2;10(9):664. doi: 10.3390/diagnostics10090664. PMID: 32887318.</p>
<p>Audience/Learners</p>	<p>Educational initiatives should focus on addressing the educational needs and practice gaps specific to the full healthcare team including rheumatologists, pulmonologists, radiologists, fellows, managed care professionals, and advanced practice providers across community academic and health systems.</p> <p>Activities tailored to a single primary target audience will be prioritized given the unique educational needs of different audiences.</p>
<p>Educational Format(s)</p>	<p>Formats may include: case-based training programs, local or regional multi-disciplinary care coordination workshops, grand rounds, satellite symposia and online activities.</p> <p>Proposals for educational programs delivered at, or aligned with, major professional congresses — including ATS, ACR, APAPP, EULAR, RhAPP, ERS, AMCP, Asembia, NAMCP, RSNA and CHEST— will also be considered.</p>
<p>Geographic Reach</p>	<p>United States</p>
<p>Available Support</p>	<p>For all programs other than satellite symposia, the amount requested from Boehringer should not exceed \$250,000.</p> <p><b>Please note that Boehringer encourages submission of grant applications with multiple sources of funding support.</b></p>
<p>Selection Criteria</p>	<p>Applications will be evaluated based upon:</p> <ul style="list-style-type: none"> <li>• Ability to meet all requirements in submission</li> <li>• Requestor’s knowledge of and experience within the therapeutic area and disease state</li> <li>• Well defined and researched gap analysis/needs assessment that specifies the current practice gap of identified learners within the educational focus indicated</li> <li>• Education focused on supporting excellence in patient care</li> </ul>

**Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)**

	<ul style="list-style-type: none"> <li>• Linkage of educational needs to practical, and measurable learning objectives</li> <li>• Incorporation of adult learning principles and instructional design method, interaction, and innovation in the educational format that reflect the preferred learning styles of the target audience</li> <li>• Outcomes measures that are in alignment with learning objectives and educational format, utilizing best practices in assessment methods</li> <li>• Audience generation methods that are specific to the activity and target audience</li> <li>• Rigor of mechanisms in place to validate content and mitigate identified relevant financial relationships, including review and revision of content as necessary to ensure a balanced view of therapeutic options and elimination of commercial bias</li> <li>• Compliance with guidelines and regulations related to CME/CE or other local governance related to medical education, as applicable</li> <li>• Fiscal responsibility and fair market value</li> </ul>
<p>Outcomes Measures</p>	<p>Up to Moore’s Level 4 (Performance-based) outcomes.</p> <p>Moore DE Jr, Green JS, Gallis HA. <i>Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities</i> <u>Contin Educ Health Prof.</u> 2009 Winter; 29 (1):1-15.</p>

**BIPI Standards for IME Applications:**

1. This RFP does not commit BIPI or its alliance partners to award a grant of any size nor to pay any costs incurred in the preparation of a response to this request. BIPI reserves the right not to fund any requests, or to review incomplete applications.
2. BIPI further reserves the right to request and to receive additional information and clarification relating to the submission; such a request would be provided by BIPI via e-mail.
3. All communications about the RFP must come exclusively to the BIPI Medical Education and Research Grants Office. Failure to comply may disqualify applicants. Applications received after the submission date or through other channels will not be considered.
4. BIPI adheres to both Federal and State Transparency Reporting Regulations and as such will report transfers of value from education grants provided to Health Care Providers and medical, scientific, and patient organizations.
5. Grant funding shall be paid directly only to the entity that is specified in the grant application as “applicant”. BIPI will not make any payments to any individuals or co-sponsors of the educational program. No grant has been awarded until a formal grant agreement has been fully executed between BIPI and the applicant.
6. All applications must have comprehensive and itemized budgets.
7. Grantees must reconcile expenses and provide an outcomes report upon completion of the BIPI-supported educational program.